LP-003 clinical trials
Also written LP-003.
How each study uses LP-003 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the LP-003 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Longbio Pharma (8) · Longbio Pharma (Suzhou) Co., Ltd. (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test LP-003.
- Nov 2026A Study of Single Dose of LP-003 in Healthy Adult SubjectsPhase 1 · Longbio Pharma
- Feb 2027A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Phase 2 · Longbio Pharma
- Jul 2027A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Characteristics of LP-003 Injection in Participants With Wheat AllergyPhase 2 · Longbio Pharma (Suzhou) Co., Ltd.
Studies
Open first, then newest update. How each study uses LP-003 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Efficacy, Safety and Pharmacokinetics of LP-003 in Peanut Allergic PatientsNot yet recruitingPhase 2Longbio Pharma (Suzhou) Co., Ltd.NCT07785063Written as LP-003 Injection
- A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Characteristics of LP-003 Injection in Participants With Wheat AllergyNot yet recruitingPhase 2Longbio Pharma (Suzhou) Co., Ltd.NCT07816432Written as LP-003 Injection
- A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Not yet recruitingPhase 2Longbio PharmaNCT07313917Written as LP-003 Injection
- Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma PatientsRecruitingPhase 2Longbio PharmaNCT07342803Written as LP-003 Injection
- Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) TreatmentCompletedPhase 2Longbio PharmaNCT06228560Written as LP-003
- A Study of Single Dose of LP-003 in Adolescent SubjectsActive, not recruitingPhase 1/2Longbio PharmaNCT07148557Written as LP-003 Dose 1 (Single)
- Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic RhinitisActive, not recruitingPhase 3Longbio PharmaNCT07291284Written as LP-003
- A Study of Single Dose of LP-003 in Healthy Adult SubjectsActive, not recruitingPhase 1Longbio PharmaNCT06604949Written as LP-003 200mg
- Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis AdultCompletedPhase 2Longbio PharmaNCT06046391Written as LP-003 dose 1
- A Study of Single and Multiple Doses of LP-003 in Healthy Adult ParticipantsCompletedPhase 1Longbio PharmaNCT06294288Written as LP-003 Dose 1 (Single)